Publications by authors named "Christine Brandquist"
Article Synopsis
- The text discusses the assessment of QTc interval prolongation risk in a clinical study for the drug odanacatib, meant for osteoporosis treatment.
- Two clinical studies were conducted to evaluate the pharmacokinetics and safety of a high dose of odanacatib, with one study comparing it to moxifloxacin, a known antibiotic.
- Results showed that the highest doses of odanacatib did not increase the risk of prolonged QT interval, and its safety profile was comparable to placebo, with only minor oral cavity side effects noted.
This open-label 2-period study assessed the effect of multiple-dose administration of rifampin, a strong cytochrome P450 3A (CYP3A) and P-glycoprotein inducer, on the pharmacokinetics of odanacatib, a cathepsin K inhibitor. In period 1, 12 healthy male subjects (mean age, 30 years) received a single dose of odanacatib 50 mg on day 1, followed by a 28-day washout. In period 2, subjects received rifampin 600 mg/day for 28 days; odanacatib 50 mg was coadministered on day 14.
View Article and Find Full Text PDFObjectives: This study was conducted in order to assess the effect of multiple doses of odanacatib, a cathepsin (Cat)-K inhibitor, on the pharmacokinetics of digoxin.
Materials: Twelve healthy male and female subjects received 0.5 mg digoxin and 50 mg odanacatib.